Guggenheim raised the firm’s price target on Maze Therapeutics (MAZE) to $58 from $46 and keeps a Buy rating on the shares after the firm discussed the upcoming MZE-829 data in APOL1 primary or diabetic AMKD with six nephrologists.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst
- Maze Therapeutics files automatic mixed securities shelf
- Maze Therapeutics Secures New $200 Million Loan Facility
- Buy Rating on Maze Therapeutics: Attractive Risk‑Reward Driven by Differentiated APOL1 Kidney Disease Therapy MZE829 and Raised $46 Target
- Maze Therapeutics price target raised to $46 from $37 at BTIG